PMID- 12784908
OWN - NLM
STAT- MEDLINE
DCOM- 20030908
LR  - 20191107
IS  - 0892-3973 (Print)
IS  - 0892-3973 (Linking)
VI  - 25
IP  - 2
DP  - 2003 May
TI  - Comparison of plasma levels of cytokines and in vitro generation of reactive 
      oxygen species after nicotine infusion in nicotine users with normal and impaired 
      renal function.
PG  - 131-44
AB  - Several in vitro and animal studies suggest effects of nicotine on the immune 
      system, but little evidence exists regarding the in vivo immunomodulation of 
      nicotine in humans. The increased use of nicotine replacement therapy to aid 
      smoking cessation claims further understanding of how nicotine affects blood 
      leukocytes. This is of particular importance when nicotine therapy is used in 
      diseases associated with alterations of the immune system, such as chronic renal 
      failure. The present study evaluates the acute effects of nicotine infusion (NI) 
      on some immunoregulatory functions in seven healthy subjects and seven patients 
      with renal failure. All subjects were nicotine users and had refrained from using 
      nicotine for 36 h before NI. Blood was collected before, immediately after, and 2 
      h after NI. Plasma concentrations of intercellular adhesion molecule-1 (ICAM-1) 
      and the cytokines interleukin-2 (IL-2), IL-4, IL-10, interferon-gamma and RANTES 
      were measured using specific immunoassays. The generation of reactive oxygen 
      species (ROS) induced by formyl-methionyl-leucyl-phenylalanine (fMLP), 
      Ristocetin, adenosine 5'-diphosphate, or collagen was registered in whole blood 
      as luminol-dependent chemiluminescence. Except for fMLP, these compounds induce 
      leukocyte ROS generation by platelet mediated mechanisms. NI did not 
      significantly affect the levels of the cytokines and ICAM-1 in any group. The 
      peak and the persistent ROS production, induced by collagen and Ristocetin, was 
      lower at some time points in patients with renal failure as compared to healthy 
      subjects. Also in patients with renal failure, both peak height and persistent 
      ROS generation induced by Ristocetin were reduced immediately after NI. Thus, 
      nicotine inhibits some of the platelet-mediated activation of leukocyte ROS 
      generation, and may be associated with platelet defects in renal failure.
FAU - Whiss, Per A
AU  - Whiss PA
AD  - Division of Pharmacology, Faculty of Health Sciences, Linkoping, Sweden. 
      per.whiss@imv.liu.se
FAU - Bengtsson, Torbjorn
AU  - Bengtsson T
FAU - Larsson, Rutger
AU  - Larsson R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cytokines)
RN  - 0 (Reactive Oxygen Species)
RN  - 6M3C89ZY6R (Nicotine)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage/therapeutic use
MH  - Adult
MH  - Cytokines/*blood/immunology
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Nicotine/*administration & dosage/therapeutic use
MH  - Reactive Oxygen Species/*blood/immunology
MH  - Renal Insufficiency/*blood/immunology
MH  - Smoking/*blood/immunology
MH  - Smoking Prevention
EDAT- 2003/06/06 05:00
MHDA- 2003/09/10 05:00
CRDT- 2003/06/06 05:00
PHST- 2003/06/06 05:00 [pubmed]
PHST- 2003/09/10 05:00 [medline]
PHST- 2003/06/06 05:00 [entrez]
AID - 10.1081/iph-120020465 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2003 May;25(2):131-44. doi: 10.1081/iph-120020465.